We Fuel a Network of Leaders that Drive Virginia Bioscience
We are made up of the people who do the research, development and commercialization of biosciences in Virginia, and the suppliers, consultants, attorneys, accountants and others who work to support the industry.
Our Sponsors
Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
-
1,451 Companies
Life science companies in Virginia.
-
$8B Industry
Life Science contributes $8B to Virginia's economy.
-
26,545 People
Employed by Life Science companies in Virginia.
-
$77,848 Average Wage
Average earnings of life science workers in Virginia.
-
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
News
10/21/2021
RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries
RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the design and development of a computer-aided 3D …
10/20/2021
ATCC Hires New Chief Commercial Officer
ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee …
10/20/2021
Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company
Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing. The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies. Additional investors in Contraline include: …
Our Premium Partners
